Product/Composition:- | Thiabendazole tablets |
---|---|
Strength:- | 500 mg |
Form:- | Tablets |
Reference Brands:- | Mintezol(US), Tebanic(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Thiabendazole inhibits microtubule formation in parasites, disrupting nutrient absorption and leading to their death. It effectively treats intestinal worms like roundworms and hookworms, as well as skin infestations. Benefits include rapid symptom relief, parasite eradication, reduced transmission, and supporting gastrointestinal and dermatological health worldwide.
Thiabendazole tablets, marketed as Mintezol and Tebanic, are approved in the US by the FDA and in the EU via EMA for treating parasitic infections. Regulatory approval requires detailed dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper compliance supports timely approval, safe use, and global availability, effectively managing intestinal and skin parasitic infections worldwide, supporting health efforts against parasitic diseases.